

References

I-217

1. Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: Final results from a phase 2 randomized study (ROMULUS). *Lancet Haematol.* 2019;19:2352-3026.
2. Sehn LH, Kamdar M, Herrera AF, et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (R/R) FL and DLBCL. *J Clin Oncol.* 2018;36(15):7507.
3. Clinical Pharmacology™ Compendium 2024. Tampa FL: Gold Standard, Inc. Polatuzumab vedotin-piiq.
4. Micromedex DrugDex Compendium®. 2024. Polatuzumab vedotin-piiq.
5. Polivy™ (polatuzumab vedotin-piiq) for injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 04/2023.
6. National Comprehensive Cancer Network (NCCN). Polatuzumab vedotin-piiq. NCCN Drugs and Biologics Compendium®. 2024.
7. Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. *J Hematol Oncol.* 2020;13(1):1-18.
8. Sawalha Y, Maddocks K. Profile of polatuzumab vedotin in the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: a brief report on the emerging clinical data. *OncoTargets & Therapy.* 2020;13:5123-5133.
9. Sehn LH, Herrera AF, Flowers CR, et al. polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma. *J Clin Oncol.* 2020;38(2):155-165.
10. Polatuzumab vedotin-piiq In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated September 28, 2020.
11. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med.* 2022;386(4):351-363.
12. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *J Clin Oncol.* 2020;38(2):155-165.
13. Felizzi F, Launonen A, Thuresson PO. Approximation of long-term survival with polatuzumab vedotin plus bendamustine and rituximab for patients with relapsed/refractory diffuse large b-cell lymphoma: results based on the GO29365 Trial. *Pharmacoecon Open.* 2023;7(1):37-46.